Femasys doubles enrolling sites to 12 in FemBloc FINALE pivotal trial for permanent birth control
Femasys doubled actively enrolling U.S. sites to 12 for its FemBloc FINALE pivotal trial in non-surgical permanent birth control. No trial results were presented; the expanded enrollment is intended to support completion of the U.S. study and an FDA filing. FemBloc is positioned as an office-based alternative to surgic